Breaking News

XOMA Wins Botulism Antitoxin Contract

Contract valued at more than $28 million

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

XOMA Ltd. has been awarded a contract to develop broad-spectrum antitoxins for the treatment of botulism poisoning. The contract is valued at more than $28 million during a five-year period. To date, XOMA has entered into four contracts totaling $120 million with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance biodefense-related product development. “The success of our prior NIAID contracts for anti-botulism an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters